NCT03884998View on ClinicalTrials.gov

Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 26, 2019

Primary Completion Date

November 28, 2025

Study Completion Date

November 28, 2025

Conditions
Chronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaIndolent Non-Hodgkin LymphomaLymphoplasmacytic LymphomaMarginal Zone LymphomaRichter Syndrome
Interventions
DRUG

Copanlisib

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (3)

91010

City of Hope Medical Center, Duarte

97239

OHSU Knight Cancer Institute, Portland

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER